FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4307831291> ?p ?o ?g. }

• W4307831291 endingPage "5023" @default.
• W4307831291 startingPage "5007" @default.
• W4307831291 abstract "Sonodynamic therapy (SDT) is emerging as a cancer treatment alternative with significant advantages over conventional therapies, including its minimally invasive and site-specific nature, its radical antitumour efficacy with minimal side effects, and its capacity to raise an antitumour immune response. The study explores the efficacy of SDT in combination with nanotechnology against pancreatic ductal adenocarcinoma.A nanoparticulate formulation (HPNP) based on a cathepsin B-degradable glutamate-tyrosine co-polymer that carries hematoporphyrin was used in this study for the SDT-based treatment of PDAC. Cathepsin B levels in BxPC-3 and PANC-1 cells were correlated to cellular uptake of HPNP. The HPNP efficiency to induce a sonodynamic effect at varying ultrasound parameters, and at different oxygenation and pH conditions, was investigated. The biodistribution, tumour accumulation profile, and antitumour efficacy of HPNP in SDT were examined in immunocompetent mice carrying bilateral ectopic murine pancreatic tumours. The immune response profile of excised tumour tissues was also examined.The HPNP formulation significantly improved cellular uptake of hematoporphyrin for both BxPC-3 and PANC-1 cells, while increase of cellular uptake was positively correlated in PANC-1 cells. There was a clear SDT-induced cytotoxicity at the ultrasound conditions tested, and the treatment impaired the capacity of both BxPC-3 and PANC-1 cells to form colonies. The overall acoustic energy and pulse length, rather than the power density, were key in eliciting the effects observed in vitro. The SDT treatment in combination with HPNP resulted in 21% and 27% reduction of the target and off-target tumour volumes, respectively, within 24 h. A single SDT treatment elicited an antitumour effect that was characterized by an SDT-induced decrease in immunosuppressive T cell phenotypes.SDT has significant potential to serve as a monotherapy or adjunctive treatment for inoperable or borderline resectable PDAC." @default.
• W4307831291 created "2022-11-06" @default.
• W4307831291 creator A5007275940 @default.
• W4307831291 creator A5009179437 @default.
• W4307831291 creator A5009957180 @default.
• W4307831291 creator A5026464483 @default.
• W4307831291 creator A5028826990 @default.
• W4307831291 creator A5029265067 @default.
• W4307831291 creator A5038361205 @default.
• W4307831291 creator A5045604232 @default.
• W4307831291 creator A5054270886 @default.
• W4307831291 creator A5065017362 @default.
• W4307831291 creator A5070979764 @default.
• W4307831291 creator A5071325305 @default.
• W4307831291 creator A5078717231 @default.
• W4307831291 creator A5091479709 @default.
• W4307831291 date "2022-11-02" @default.
• W4307831291 modified "2023-10-18" @default.
• W4307831291 title "Nanotechnology-augmented sonodynamic therapy and associated immune-mediated effects for the treatment of pancreatic ductal adenocarcinoma" @default.
• W4307831291 cites W1577340220 @default.
• W4307831291 cites W1855690543 @default.
• W4307831291 cites W1870490536 @default.
• W4307831291 cites W1999969617 @default.
• W4307831291 cites W2031017289 @default.
• W4307831291 cites W2117115065 @default.
• W4307831291 cites W2127833553 @default.
• W4307831291 cites W2137070227 @default.
• W4307831291 cites W2144810538 @default.
• W4307831291 cites W2149828028 @default.
• W4307831291 cites W2154685237 @default.
• W4307831291 cites W2164977248 @default.
• W4307831291 cites W2277655379 @default.
• W4307831291 cites W2403004483 @default.
• W4307831291 cites W2533941196 @default.
• W4307831291 cites W2550304925 @default.
• W4307831291 cites W2592581620 @default.
• W4307831291 cites W2605556350 @default.
• W4307831291 cites W2790181787 @default.
• W4307831291 cites W2794708707 @default.
• W4307831291 cites W2885721684 @default.
• W4307831291 cites W2886752365 @default.
• W4307831291 cites W2895684352 @default.
• W4307831291 cites W2900885448 @default.
• W4307831291 cites W2910310961 @default.
• W4307831291 cites W2942900492 @default.
• W4307831291 cites W2946663348 @default.
• W4307831291 cites W2990050632 @default.
• W4307831291 cites W2994949240 @default.
• W4307831291 cites W3109529427 @default.
• W4307831291 cites W3111270829 @default.
• W4307831291 cites W3120831468 @default.
• W4307831291 cites W3121841314 @default.
• W4307831291 cites W3145293949 @default.
• W4307831291 cites W3172719969 @default.
• W4307831291 cites W3198466271 @default.
• W4307831291 cites W3203685240 @default.
• W4307831291 doi "https://doi.org/10.1007/s00432-022-04418-y" @default.
• W4307831291 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36319895" @default.
• W4307831291 hasPublicationYear "2022" @default.
• W4307831291 type Work @default.
• W4307831291 citedByCount "3" @default.
• W4307831291 countsByYear W43078312912023 @default.
• W4307831291 crossrefType "journal-article" @default.
• W4307831291 hasAuthorship W4307831291A5007275940 @default.
• W4307831291 hasAuthorship W4307831291A5009179437 @default.
• W4307831291 hasAuthorship W4307831291A5009957180 @default.
• W4307831291 hasAuthorship W4307831291A5026464483 @default.
• W4307831291 hasAuthorship W4307831291A5028826990 @default.
• W4307831291 hasAuthorship W4307831291A5029265067 @default.
• W4307831291 hasAuthorship W4307831291A5038361205 @default.
• W4307831291 hasAuthorship W4307831291A5045604232 @default.
• W4307831291 hasAuthorship W4307831291A5054270886 @default.
• W4307831291 hasAuthorship W4307831291A5065017362 @default.
• W4307831291 hasAuthorship W4307831291A5070979764 @default.
• W4307831291 hasAuthorship W4307831291A5071325305 @default.
• W4307831291 hasAuthorship W4307831291A5078717231 @default.
• W4307831291 hasAuthorship W4307831291A5091479709 @default.
• W4307831291 hasBestOaLocation W43078312911 @default.
• W4307831291 hasConcept C121608353 @default.
• W4307831291 hasConcept C126322002 @default.
• W4307831291 hasConcept C142724271 @default.
• W4307831291 hasConcept C204787440 @default.
• W4307831291 hasConcept C2778448707 @default.
• W4307831291 hasConcept C2780210213 @default.
• W4307831291 hasConcept C502942594 @default.
• W4307831291 hasConcept C71924100 @default.
• W4307831291 hasConceptScore W4307831291C121608353 @default.
• W4307831291 hasConceptScore W4307831291C126322002 @default.
• W4307831291 hasConceptScore W4307831291C142724271 @default.
• W4307831291 hasConceptScore W4307831291C204787440 @default.
• W4307831291 hasConceptScore W4307831291C2778448707 @default.
• W4307831291 hasConceptScore W4307831291C2780210213 @default.
• W4307831291 hasConceptScore W4307831291C502942594 @default.
• W4307831291 hasConceptScore W4307831291C71924100 @default.
• W4307831291 hasFunder F4320334627 @default.
• W4307831291 hasIssue "8" @default.
• W4307831291 hasLocation W43078312911 @default.
• W4307831291 hasLocation W43078312912 @default.

• next